Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3958904,1.0 V,The limit of quantitation for nicardipine at 1.0 V versus Ag/AgCl was 8 ng/mL and the linear dynamic range was 15-150 ng/mL.,Intranasal delivery of nicardipine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[ng] / [ml],8,4745,DB00622,Nicardipine
,3958904,linear dynamic,The limit of quantitation for nicardipine at 1.0 V versus Ag/AgCl was 8 ng/mL and the linear dynamic range was 15-150 ng/mL.,Intranasal delivery of nicardipine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[ng] / [ml],15-150,4746,DB00622,Nicardipine
,3958904,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 5110 ng . min/mL as compared to 3730 ng . min/mL following intranasal dosing.,Intranasal delivery of nicardipine in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[min·ng] / [ml],5110,4747,DB00622,Nicardipine
,3958904,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 5110 ng . min/mL as compared to 3730 ng . min/mL following intranasal dosing.,Intranasal delivery of nicardipine in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[min·ng] / [ml],3730,4748,DB00622,Nicardipine
,3958904,bioavailability,This corresponds to a bioavailability of 73%.,Intranasal delivery of nicardipine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),%,73,4749,DB00622,Nicardipine
,9832368,recovery,The recovery of nicardipine from plasma samples using selective SPE was 91+/-6.0% and had less interfering compounds in the HPLC analysis compared to the use of liquid-liquid (L/L) extraction.,Extraction and quantification of nicardipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832368/),%,91,8754,DB00622,Nicardipine
,6502496,extraction efficiencies,"The extraction efficiencies for nicardipine and its pyridine metabolite II from 1 mL of plasma were 77.4 and 81.1%, respectively.",A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502496/),%,77.4,15940,DB00622,Nicardipine
,6502496,extraction efficiencies,"The extraction efficiencies for nicardipine and its pyridine metabolite II from 1 mL of plasma were 77.4 and 81.1%, respectively.",A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502496/),%,81.1,15941,DB00622,Nicardipine
,7426117,terminal half-life,The terminal half-life of the drug after i.v. administration to humans was about 1 h.,"Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426117/),h,1,20935,DB00622,Nicardipine
,3588513,Emax,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,100,24274,DB00622,Nicardipine
,3588513,IC50,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,10,24275,DB00622,Nicardipine
,3588513,IC50,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,65,24276,DB00622,Nicardipine
,3588513,Emax,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,68,24277,DB00622,Nicardipine
,3588513,Emax,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,78,24278,DB00622,Nicardipine
,3588513,IC50,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,21,24279,DB00622,Nicardipine
,3588513,IC50,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,136,24280,DB00622,Nicardipine
,3588513,Emax,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,33,24281,DB00622,Nicardipine
,3588513,Emax,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,56,24282,DB00622,Nicardipine
,3588513,IC50,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,6,24283,DB00622,Nicardipine
,3588513,IC50,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,81,24284,DB00622,Nicardipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,56,24285,DB00622,Nicardipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,16,24286,DB00622,Nicardipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,29,24287,DB00622,Nicardipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],290,24288,DB00622,Nicardipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],61,24289,DB00622,Nicardipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],177,24290,DB00622,Nicardipine
,2328554,terminal elimination half-life,"The terminal elimination half-life in this group varied from 0.8 to 60.2 hours (median, 11.7 hours), compared with 0.6 to 4.1 hours (median, 1.4 hours) in the group of eight subjects with normal liver function.",The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328554/),h,11.7,27555,DB00622,Nicardipine
,2328554,terminal elimination half-life,"The terminal elimination half-life in this group varied from 0.8 to 60.2 hours (median, 11.7 hours), compared with 0.6 to 4.1 hours (median, 1.4 hours) in the group of eight subjects with normal liver function.",The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328554/),h,0.6 to 4.1,27556,DB00622,Nicardipine
,2328554,terminal elimination half-life,"The terminal elimination half-life in this group varied from 0.8 to 60.2 hours (median, 11.7 hours), compared with 0.6 to 4.1 hours (median, 1.4 hours) in the group of eight subjects with normal liver function.",The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328554/),h,1.4,27557,DB00622,Nicardipine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],39.8,32819,DB00622,Nicardipine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],28.3,32820,DB00622,Nicardipine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],32.6,32821,DB00622,Nicardipine
,9350366,half-life,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),min,14,32822,DB00622,Nicardipine
,9350366,clearance,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[l] / [min],2.1,32823,DB00622,Nicardipine
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,77.56,36212,DB00622,Nicardipine
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,84.23,36213,DB00622,Nicardipine
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,83.94,36214,DB00622,Nicardipine
,12583003,half-life (t(1/2),The results inferred that NC is rapidly absorbed in rabbits and has a short half-life (t(1/2) = 1.34 h).,A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),h,1.34,36215,DB00622,Nicardipine
,3593894,steady-state bioavailability,"The steady-state bioavailability of nicardipine was shown to be dose-dependent and averaged 19 per cent (10 mg), 22 per cent (20 mg), 28 per cent (30 mg), and 38 per cent (40 mg).",Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593894/),%,19,45498,DB00622,Nicardipine
,3593894,steady-state bioavailability,"The steady-state bioavailability of nicardipine was shown to be dose-dependent and averaged 19 per cent (10 mg), 22 per cent (20 mg), 28 per cent (30 mg), and 38 per cent (40 mg).",Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593894/),%,22,45499,DB00622,Nicardipine
,3593894,steady-state bioavailability,"The steady-state bioavailability of nicardipine was shown to be dose-dependent and averaged 19 per cent (10 mg), 22 per cent (20 mg), 28 per cent (30 mg), and 38 per cent (40 mg).",Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593894/),%,28,45500,DB00622,Nicardipine
,3593894,steady-state bioavailability,"The steady-state bioavailability of nicardipine was shown to be dose-dependent and averaged 19 per cent (10 mg), 22 per cent (20 mg), 28 per cent (30 mg), and 38 per cent (40 mg).",Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593894/),%,38,45501,DB00622,Nicardipine
,18819472,CL/F,"Typical value of CL/F and V/F was 21.7 L x h(-1) and 241 L, inter-patient variability (RSD) in CL/F and V/F was 41.6% and 49.7%, respectively.",[Population pharmacokinetics of tacrolimus in Chinese renal transplant patients]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819472/),[l] / [h],21.7,59408,DB00622,Nicardipine
,18819472,V/F,"Typical value of CL/F and V/F was 21.7 L x h(-1) and 241 L, inter-patient variability (RSD) in CL/F and V/F was 41.6% and 49.7%, respectively.",[Population pharmacokinetics of tacrolimus in Chinese renal transplant patients]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819472/),l,241,59409,DB00622,Nicardipine
,8866038,tmax,"In the food-effect study ratios of least-squares means (Zenith under fed conditions/Zenith under fasted conditions) were 0.62 for AUCt, 0.65 for AUCinfinity, and 0.40 for Cmax, with tmax delayed from 0.906 +/- 0.337 h (Zenith under fasted conditions) to 2.33 +/- 0.717 h (Zenith under fed conditions) and 2.84 +/- 0.834 h (Syntex under fed conditions).",Bioequivalence of two orally administered nicardipine products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866038/),h,0.906,65088,DB00622,Nicardipine
,8866038,tmax,"In the food-effect study ratios of least-squares means (Zenith under fed conditions/Zenith under fasted conditions) were 0.62 for AUCt, 0.65 for AUCinfinity, and 0.40 for Cmax, with tmax delayed from 0.906 +/- 0.337 h (Zenith under fasted conditions) to 2.33 +/- 0.717 h (Zenith under fed conditions) and 2.84 +/- 0.834 h (Syntex under fed conditions).",Bioequivalence of two orally administered nicardipine products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866038/),h,2.33,65089,DB00622,Nicardipine
,8866038,tmax,"In the food-effect study ratios of least-squares means (Zenith under fed conditions/Zenith under fasted conditions) were 0.62 for AUCt, 0.65 for AUCinfinity, and 0.40 for Cmax, with tmax delayed from 0.906 +/- 0.337 h (Zenith under fasted conditions) to 2.33 +/- 0.717 h (Zenith under fed conditions) and 2.84 +/- 0.834 h (Syntex under fed conditions).",Bioequivalence of two orally administered nicardipine products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866038/),h,2.84,65090,DB00622,Nicardipine
,3598907,cardiac output,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[l] / [min],1.63,65217,DB00622,Nicardipine
,3598907,heart rate,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[beats] / [min],75,65218,DB00622,Nicardipine
,3598907,dP/dt,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[hg·mm] / [s],741,65219,DB00622,Nicardipine
,3598907,blood flows,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[ml] / [min],39,65220,DB00622,Nicardipine
,3598907,initial volume of distribution,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,11.6,65221,DB00622,Nicardipine
,3598907,initial volume of distribution,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,8.9,65222,DB00622,Nicardipine
,3598907,total clearance,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[l] / [h],28.5,65223,DB00622,Nicardipine
,3598907,total clearance,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[l] / [h],19.2,65224,DB00622,Nicardipine
,3598907,volume of distribution at steady state,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,50.0,65225,DB00622,Nicardipine
,3598907,volume of distribution at steady state,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,29.2,65226,DB00622,Nicardipine
,2301242,duration of action,The mean duration of action after an intravenous bolus dose was 24 +/- 5 minutes.,Acute pharmacokinetic and hemodynamic effects of intravenous bolus dosing of nicardipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301242/),min,24,74351,DB00622,Nicardipine
,7210702,cumulative excretion,"4. In rats receiving 3 mg/kg/day for seven days, cumulative excretion was 97.3% administered drug, indicating no tendency to accumulation.","Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs and humans. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210702/),%,97.3,80567,DB00622,Nicardipine
,24131296,BrM/MP ratio,The BrM/MP ratio was 0.06 to 0.30.,Placental transfer of intravenous nicardipine and disposition into breast milk during the control of hypertension in women with pre-eclampsia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24131296/),,0.06 to 0.30,84919,DB00622,Nicardipine
,11707062,V1,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],1.83,85950,DB00622,Nicardipine
,11707062,V2,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],22.6,85951,DB00622,Nicardipine
,11707062,Q,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [h·kg],0.629,85952,DB00622,Nicardipine
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB00622,Nicardipine
,10084158,nasal bioavailability,"The nasal bioavailability of nicardipine from plain buffered solution was 44%, and increased steadily to 56-79% in direct proportion to the amount of PEG 400 added.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,44,104913,DB00622,Nicardipine
,10084158,nasal bioavailability,"The nasal bioavailability of nicardipine from plain buffered solution was 44%, and increased steadily to 56-79% in direct proportion to the amount of PEG 400 added.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,56-79,104914,DB00622,Nicardipine
,10084158,bioavailability,"Verapamil, on the other hand, exhibited an intranasal bioavailability of 52% in the absence of PEG 400, and between 61-68% in the presence of increasing concentrations of PEG 400.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,52,104915,DB00622,Nicardipine
,10084158,bioavailability,"Verapamil, on the other hand, exhibited an intranasal bioavailability of 52% in the absence of PEG 400, and between 61-68% in the presence of increasing concentrations of PEG 400.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,61-68,104916,DB00622,Nicardipine
,8061850,terminal half-life,"After intravenous infusion, the disposition of spirapril is monophasic with a terminal half-life of 20-50 minutes.",Spirapril: pharmacokinetic properties and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),min,20-50,108588,DB00622,Nicardipine
,8061850,Plasma clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],56,108589,DB00622,Nicardipine
,8061850,renal clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],11,108590,DB00622,Nicardipine
,8061850,volume of distribution,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,28,108591,DB00622,Nicardipine
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,2,108592,DB00622,Nicardipine
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,35,108593,DB00622,Nicardipine
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],10,108594,DB00622,Nicardipine
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],7.6,108595,DB00622,Nicardipine
,8061850,volume of distribution,The volume of distribution was 43 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,43,108596,DB00622,Nicardipine
,8061850,bioavailability,The bioavailability of orally administered spirapril was 50% whereas the bioavailability of orally administered spiraprilat was virtually zero.,Spirapril: pharmacokinetic properties and drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),%,50,108597,DB00622,Nicardipine
,16280265,m/,Selected ion monitoring (SIM) in positive mode was used for analyte quantification at m/z 480.2 for nicardipine and m/z 256.4 for diphenhydramine.,Liquid chromatography-mass spectrometry method for the determination of nicardipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280265/),,480.2,109486,DB00622,Nicardipine
less,16280265,run time,The run time was less than 5 min.,Liquid chromatography-mass spectrometry method for the determination of nicardipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280265/),min,5,109487,DB00622,Nicardipine
,2598970,total plasma clearance,"The total plasma clearance was about 800 ml/min, the volume of distribution was of the order of 1 l/kg and the half-life of beta-elimination ranged from 4 to 5 h.",Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598970/),[ml] / [min],800,110063,DB00622,Nicardipine
,2598970,volume of distribution,"The total plasma clearance was about 800 ml/min, the volume of distribution was of the order of 1 l/kg and the half-life of beta-elimination ranged from 4 to 5 h.",Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598970/),[l] / [kg],1,110064,DB00622,Nicardipine
,2598970,half-life of beta-elimination,"The total plasma clearance was about 800 ml/min, the volume of distribution was of the order of 1 l/kg and the half-life of beta-elimination ranged from 4 to 5 h.",Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598970/),h,4 to 5,110065,DB00622,Nicardipine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB00622,Nicardipine
,9248767,Relative bioavailability,"Relative bioavailability of the sustained-release preparation vs the conventional preparation was 28% and 44% for (+)- and (-)-nicardipine, respectively, for the 40-mg dose.",Pharmacokinetics of nicardipine enantiomers in healthy young volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248767/),%,28,137392,DB00622,Nicardipine
,9248767,Relative bioavailability,"Relative bioavailability of the sustained-release preparation vs the conventional preparation was 28% and 44% for (+)- and (-)-nicardipine, respectively, for the 40-mg dose.",Pharmacokinetics of nicardipine enantiomers in healthy young volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248767/),%,44,137393,DB00622,Nicardipine
,10412892,steady state peak plasma concentrations,"Pharmacokinetic modeling based on compartment analysis and supported by analog computer and digital simulation technique showed that the target steady state peak plasma concentrations of 32 microg/l and trough plasma concentration of 7 microg/l would be maintained if nicardipine were incorporated in a formulation releasing the drug as follows: 25% after 1 h, 40% after 2 h, 65% after 4 h, 80% after 6 h, 90% after 8 h and 100% by 12 h.",Formulation of controlled release microspheres containing nicardipine: the role of pharmacokinetic modeling and computer simulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10412892/),[μg] / [l],32,139423,DB00622,Nicardipine
,10412892,trough plasma concentration,"Pharmacokinetic modeling based on compartment analysis and supported by analog computer and digital simulation technique showed that the target steady state peak plasma concentrations of 32 microg/l and trough plasma concentration of 7 microg/l would be maintained if nicardipine were incorporated in a formulation releasing the drug as follows: 25% after 1 h, 40% after 2 h, 65% after 4 h, 80% after 6 h, 90% after 8 h and 100% by 12 h.",Formulation of controlled release microspheres containing nicardipine: the role of pharmacokinetic modeling and computer simulation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10412892/),[μg] / [l],7,139424,DB00622,Nicardipine
,1888642,plasma clearance,"2. The plasma clearance of nicardipine was significantly lower at 6.5 ml min-1 kg-1 in patients with impaired renal function, compared with a mean value of 10.4 in patients with normal renal function and with 12.5 ml min-1 kg-1 in patients on regular haemodialysis treatment.",Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888642/),[ml] / [kg·min],6.5,140163,DB00622,Nicardipine
,1888642,plasma clearance,"2. The plasma clearance of nicardipine was significantly lower at 6.5 ml min-1 kg-1 in patients with impaired renal function, compared with a mean value of 10.4 in patients with normal renal function and with 12.5 ml min-1 kg-1 in patients on regular haemodialysis treatment.",Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888642/),[ml] / [kg·min],10.4,140164,DB00622,Nicardipine
,1888642,plasma clearance,"2. The plasma clearance of nicardipine was significantly lower at 6.5 ml min-1 kg-1 in patients with impaired renal function, compared with a mean value of 10.4 in patients with normal renal function and with 12.5 ml min-1 kg-1 in patients on regular haemodialysis treatment.",Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888642/),[ml] / [kg·min],12.5,140165,DB00622,Nicardipine
,20824619,absolute oral bioavailability (F),"However, after oral administration of nicardipine with 1 mg/kg of oral lovastatin, the AUC of nicardipine was significantly greater (by 67.4%), and the extent of absolute oral bioavailability (F) of nicardipine was increased (by 38.5%).",Effects of lovastatin on the pharmacokinetics of nicardipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20824619/),%,38.5,147218,DB00622,Nicardipine
,12584860,RSD,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,5.25,147532,DB00622,Nicardipine
,12584860,RSD,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,8.97,147533,DB00622,Nicardipine
,12584860,relative recoveries,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,99.99,147534,DB00622,Nicardipine
,12584860,relative recoveries,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,97.10,147535,DB00622,Nicardipine
,12584860,Tmax,"The mean Tmax, Cmax and AUC values were (2.49 +/- 0.03) h, (134 +/- 2) ng.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),h,2.49,147536,DB00622,Nicardipine
,7210701,rate of metabolism,"2. The rate of metabolism of the drug in rat liver was 1.76 mumol/g tissue per 20 min, while the values in the intestine, kidney, lung and blood were less than 0.1 mumol/g tissue per 20 min, suggesting that the first-pass effect observed in vivo was due mainly to metabolism of the drug in the liver.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],1.76,171655,DB00622,Nicardipine
less,7210701,rate of metabolism,"2. The rate of metabolism of the drug in rat liver was 1.76 mumol/g tissue per 20 min, while the values in the intestine, kidney, lung and blood were less than 0.1 mumol/g tissue per 20 min, suggesting that the first-pass effect observed in vivo was due mainly to metabolism of the drug in the liver.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],0.1,171656,DB00622,Nicardipine
,7210701,rates of liver metabolism,"3. The rates of liver metabolism were 1.76, 0.45 and 0.55 mumol/g tissue per 20 min in rats, dogs and monkeys, respectively.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],1.76,171657,DB00622,Nicardipine
,7210701,rates of liver metabolism,"3. The rates of liver metabolism were 1.76, 0.45 and 0.55 mumol/g tissue per 20 min in rats, dogs and monkeys, respectively.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],0.45,171658,DB00622,Nicardipine
,7210701,rates of liver metabolism,"3. The rates of liver metabolism were 1.76, 0.45 and 0.55 mumol/g tissue per 20 min in rats, dogs and monkeys, respectively.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],0.55,171659,DB00622,Nicardipine
,7210701,plasma clearance,"This species difference correlates well with the differences in plasma clearance values, which were 197, 37 and 27 ml/min per kg in rats, dogs and monkeys, respectively, after i.v. administration of nicardipine hydrochloride (0.4 mg/kg).","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[ml] / [kg·min],197,171660,DB00622,Nicardipine
,7210701,plasma clearance,"This species difference correlates well with the differences in plasma clearance values, which were 197, 37 and 27 ml/min per kg in rats, dogs and monkeys, respectively, after i.v. administration of nicardipine hydrochloride (0.4 mg/kg).","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[ml] / [kg·min],37,171661,DB00622,Nicardipine
,7210701,plasma clearance,"This species difference correlates well with the differences in plasma clearance values, which were 197, 37 and 27 ml/min per kg in rats, dogs and monkeys, respectively, after i.v. administration of nicardipine hydrochloride (0.4 mg/kg).","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[ml] / [kg·min],27,171662,DB00622,Nicardipine
,3716455,total recovered radioactivity,Mean total recovered radioactivity amounted to 94.8%.,The metabolism of nicardipine hydrochloride in healthy male volunteers. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3716455/),%,94.8,179893,DB00622,Nicardipine
,8201530,t1/2 alpha,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),min,4.9,184827,DB00622,Nicardipine
,8201530,t1/2 beta,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),h,2.76,184828,DB00622,Nicardipine
,8201530,Vdss,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[l] / [kg],3.86,184829,DB00622,Nicardipine
,8201530,plasma clearance,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[l] / [kg],2.22,184830,DB00622,Nicardipine
,8201530,AUC,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[h·ng] / [ml],1445,184831,DB00622,Nicardipine
,8201530,maximum plasma concentration,"After 30 mg kg-1 oral dose, maximum plasma concentration, tmax and AUC of YM-21095 were 28.8 +/- 9.6 ng mL-1, 0.25 h and 23.6 +/- 7.7 ng h mL-1, respectively.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[ng] / [ml],28.8,184832,DB00622,Nicardipine
,8201530,tmax,"After 30 mg kg-1 oral dose, maximum plasma concentration, tmax and AUC of YM-21095 were 28.8 +/- 9.6 ng mL-1, 0.25 h and 23.6 +/- 7.7 ng h mL-1, respectively.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),h,0.25,184833,DB00622,Nicardipine
,8201530,AUC,"After 30 mg kg-1 oral dose, maximum plasma concentration, tmax and AUC of YM-21095 were 28.8 +/- 9.6 ng mL-1, 0.25 h and 23.6 +/- 7.7 ng h mL-1, respectively.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[h·ng] / [ml],23.6,184834,DB00622,Nicardipine
,8201530,Systemic bioavailability,Systemic bioavailability as determined on the basis of the ratio of AUC after intravenous and oral dose was 0.16 +/- 0.04%.,"Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),%,0.16,184835,DB00622,Nicardipine
,8201530,Maximum plasma concentration,"Maximum plasma concentration of YM-21095 after 30 mg kg-1 oral dose to monkeys was 71.8 +/- 41.5 ng mL-1, which was reached 0.5 h after the dose.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[ng] / [ml],71.8,184836,DB00622,Nicardipine
,3709609,Plasma clearance,"Plasma clearance ranged from 5-12 ml/min/kg, and appeared lower than previously reported volunteer data.","Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709609/),[ml] / [kg·min],5-12,204216,DB00622,Nicardipine
,8314198,hepatic extraction ratio,"The hepatic extraction ratio was around 70% for the first 3 min, then decreased and remained stable thereafter, around 45%, showing a non linear first-pass metabolism pattern.",Clinical pharmacology of nicardipine in liver transplant patients. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314198/),%,70,208904,DB00622,Nicardipine
,8314198,hepatic extraction ratio,"The hepatic extraction ratio was around 70% for the first 3 min, then decreased and remained stable thereafter, around 45%, showing a non linear first-pass metabolism pattern.",Clinical pharmacology of nicardipine in liver transplant patients. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314198/),%,45,208905,DB00622,Nicardipine
,8314198,Plasma hepatic clearance,"Plasma hepatic clearance of nicardipine (699-850 ml/min) was close to total plasma clearance throughout the study (978 +/- 222 ml/min, from 71 to 87%) and half of the estimated hepatic plasma flow values at the same times (1467-1770 ml/min, from 44 to 51%).",Clinical pharmacology of nicardipine in liver transplant patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314198/),[ml] / [min],699-850,208906,DB00622,Nicardipine
,8314198,Plasma hepatic clearance,"Plasma hepatic clearance of nicardipine (699-850 ml/min) was close to total plasma clearance throughout the study (978 +/- 222 ml/min, from 71 to 87%) and half of the estimated hepatic plasma flow values at the same times (1467-1770 ml/min, from 44 to 51%).",Clinical pharmacology of nicardipine in liver transplant patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314198/),[ml] / [min],978,208907,DB00622,Nicardipine
,8314198,hepatic plasma flow,"Plasma hepatic clearance of nicardipine (699-850 ml/min) was close to total plasma clearance throughout the study (978 +/- 222 ml/min, from 71 to 87%) and half of the estimated hepatic plasma flow values at the same times (1467-1770 ml/min, from 44 to 51%).",Clinical pharmacology of nicardipine in liver transplant patients. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314198/),[ml] / [min],1467-1770,208908,DB00622,Nicardipine
,9861491,recovery,The recovery of nicardipine was 92.8-100.8% for plasma.,A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),%,92.8-100.8,210367,DB00622,Nicardipine
,9861491,Tmax,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),h,1.6,210368,DB00622,Nicardipine
,9861491,Cmax,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),[ng] / [ml],109.8,210369,DB00622,Nicardipine
,9861491,T1/2,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),h,5.35,210370,DB00622,Nicardipine
,9861491,AUC0-->infinity,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),[ng] / [h·mi],322.1,210371,DB00622,Nicardipine
,8032494,limit of detection,The limit of detection is 0.5 ng/ml for both products.,Capillary gas chromatographic determination with nitrogen-phosphorus detection of the calcium antagonist nicardipine and its pyridine metabolite M-5 in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032494/),[ng] / [ml],0.5,218193,DB00622,Nicardipine
,8360844,total body clearance,The results indicate that the average total body clearance of nicardipine is 0.920 L/h/kg and the volume of distribution is 0.275 L/kg.,Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8360844/),[l] / [h·kg],0.920,243666,DB00622,Nicardipine
,8360844,volume of distribution,The results indicate that the average total body clearance of nicardipine is 0.920 L/h/kg and the volume of distribution is 0.275 L/kg.,Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8360844/),[l] / [kg],0.275,243667,DB00622,Nicardipine
,8360844,mean residence time,"Nicardipine hydrochloride has a mean residence time in the body of 1.27 h, of which 0.324 h were spent in the systemic circulation and the remainder in the periphery.",Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8360844/),h,1.27,243668,DB00622,Nicardipine
,8360844,mean residence time,"Nicardipine hydrochloride has a mean residence time in the body of 1.27 h, of which 0.324 h were spent in the systemic circulation and the remainder in the periphery.",Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8360844/),h,0.324,243669,DB00622,Nicardipine
,10728516,half-life,It has limited effects on myocardial contractility; is available in a powder-filled capsule and has a half-life of 6 to 8 hours.,Initial experience with isradipine for the treatment of hypertension in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728516/),h,6 to 8,255688,DB00622,Nicardipine
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,40 to 60,259217,DB00622,Nicardipine
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,10-20,259218,DB00622,Nicardipine
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,15-30,259219,DB00622,Nicardipine
,3937500,volumes of distribution,"Protein binding is high but does not interfere in the distribution; the volumes of distribution of bepridil, diltiazem and verapamil are large (4-5 l/kg); those of nifedipine and nicardipine are smaller (l l/kg).",[Clinical pharmacology of calcium inhibitors]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),[l] / [kg],4-5,259220,DB00622,Nicardipine
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),h,1 to 5,259221,DB00622,Nicardipine
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),d,2 to 3,259222,DB00622,Nicardipine
,6527979,Bioavailability,Bioavailability ranged from 15-45% approximately over the dose range 10-40 mg.,Pharmacokinetics of nicardipine following oral and intravenous administration in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527979/),%,15-45,261771,DB00622,Nicardipine
